Tesamorelin

FDA-approved GHRH analog with the strongest IGF-1 response of any peptide in its class.

Overview

Tesamorelin is a synthetic analog of human growth hormone releasing hormone (GHRH) and is the only FDA-approved peptide in the GHRH class, originally developed and branded as Egrifta for HIV-associated visceral fat accumulation. It has become widely used off-label in the optimization and longevity community for its strong effect on IGF-1 and its favorable safety profile relative to exogenous growth hormone.

Compared to other GH secretagogues, tesamorelin is distinctive for the magnitude of IGF-1 elevation it produces - commonly 40–80% above baseline at standard 1–2 mg nightly doses in responders. It works by stimulating the pituitary to release endogenous growth hormone in natural pulsatile fashion, which many clinicians consider a more physiologic approach than injecting recombinant HGH directly.

Because the IGF-1 response is measurable and quantifiable, tesamorelin is a peptide where blood work genuinely matters. Users who track IGF-1 at baseline and at the 6-week mark can see directly whether their protocol is producing the expected pharmacologic effect, which is rarely possible with most peptides.

Mechanism of Action

Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating the release of endogenous growth hormone in natural pulses. This elevates circulating IGF-1, which mediates most of the downstream effects associated with growth hormone - lipolysis (particularly visceral fat), improved body composition, and enhanced sleep quality. The pulsatile release pattern avoids the tonic elevation seen with exogenous HGH.

Community Usage Patterns

Standard dosing is 1–2 mg subcutaneously once daily before bed, on an empty stomach (3-hour fasted window). Most users run it 5–7 nights per week. Baseline IGF-1 is drawn before starting; the 6-week draw is the primary assessment of response. Cycles typically run 3–6 months, sometimes with structured off-cycles. Monitoring fasting glucose and HbA1c is important because any growth-hormone-stimulating compound can reduce insulin sensitivity.

Education only - not medical advice. Any protocol change should involve your licensed provider.

Deep Dive

The GHRH analog design and why it matters

Tesamorelin is a stabilized analog of the full 44-amino-acid human growth hormone releasing hormone, GHRH(1-44). Native GHRH is cleaved within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4) at its N-terminus, which is why the natural hormone is not viable as a practical injectable. Tesamorelin addresses this by anchoring a trans-3-hexenoic acid group to the N-terminal tyrosine, a modification that shields the molecule from DPP-4 degradation and extends its functional life enough to produce a durable pituitary signal.

The detail that matters most is where it acts. Because tesamorelin works one step upstream, at the pituitary GHRH receptor rather than at peripheral growth hormone receptors, the body's own regulatory brakes stay intact. Somatostatin tone and IGF-1 negative feedback still cap how much growth hormone the pituitary will release, so the system is self-limiting in a way that injected recombinant growth hormone is not. This is the mechanistic basis for the common description of GHRH analogs as producing a more physiologic, pulsatile growth hormone profile. It does not make tesamorelin risk-free, but it does change the shape of the risk.

What the human trials actually show, and in whom

Tesamorelin has something most research peptides lack: large, randomized, double-blind, placebo-controlled Phase 3 trials behind it. In the pivotal trial (Falutz et al., New England Journal of Medicine, 2007), 412 HIV-positive adults with excess abdominal fat received 2 mg daily for 26 weeks. Visceral adipose tissue fell 15.2% on tesamorelin while rising 5.0% on placebo, triglycerides and the cholesterol ratio improved, and IGF-1 rose sharply, on the order of 80 to 90 percent. A second Phase 3 trial and a pooled analysis of roughly 816 patients (Falutz et al., 2010) confirmed the visceral-fat effect and characterized about a year of safety data.

Two findings from this body of work are essential context. First, the benefit is not durable. In the extension data, visceral fat re-accumulated toward baseline after the drug was stopped, meaning any effect is contingent on continued use. Second, later mechanistic work extended the story to the liver: in a randomized trial of about 61 people with HIV-associated fatty liver disease (Stanley et al., Lancet HIV, 2019), tesamorelin reduced liver fat by roughly 32% from baseline while it rose on placebo, a net relative reduction of about 37% over 12 months.

The honest headline is that essentially all of tesamorelin's robust human evidence comes from a single population, people with HIV-associated fat accumulation. That is who it was studied in and who it is approved for.

The evidence gap outside HIV

Tesamorelin is used widely off-label in longevity and body-composition circles, but the human data supporting that use is thin. The most substantial non-HIV study is a randomized controlled trial in 152 older adults (Baker et al., Archives of Neurology, 2012), in which 20 weeks of tesamorelin at 1 mg nightly produced a favorable effect on a composite of cognitive function, driven mainly by executive function, in both healthy seniors and adults with mild cognitive impairment. It also raised IGF-1 by about 117% while keeping it within the physiological range and reduced body fat by roughly 7%. It is a genuine, well-run result, but it is one trial with cognitive endpoints, not a validation of tesamorelin for fat loss, athletic performance, or healthspan in the general population.

There are no large randomized trials of tesamorelin in healthy athletes or for anti-aging use. Everything beyond the HIV and cognition data is extrapolation from mechanism. Holding that distinction is exactly what separates an informed tracking decision from a marketing claim, and it is a question worth raising with a licensed clinician before assuming the HIV results transfer.

Biomarkers: reading the response and the risk

IGF-1 is the primary readout, and timing is what makes it interpretable. IGF-1 integrates the pulsatile growth hormone signal into a stable daily average, so it settles at a new steady state within a few weeks, which is why a follow-up draw around the six-week mark is the conventional checkpoint. IGF-1 is strongly age-dependent, so a result is read against an age-adjusted reference range rather than an absolute number. In tracking discussions, IGF-1 is commonly interpreted against the upper part of the age-appropriate range rather than pushed above it, partly because large epidemiologic analyses (Renehan et al., Lancet, 2004) have linked higher circulating IGF-1 to a modest increase in the risk of certain cancers. That is an association, not proof of causation, but it is a reasonable input for a conversation with a clinician. IGFBP-3 is often tracked alongside IGF-1 because most IGF-1 circulates bound to it.

The glucose panel matters for a different reason. Growth hormone is counter-regulatory to insulin, so any agent that raises it can, in principle, push glucose handling in the wrong direction. Notably, the pivotal HIV trials did not show significant worsening of fasting glucose or HbA1c, but growth hormone stimulation has raised fasting insulin in some studies, and the approved labeling still advises monitoring glucose. Tracking fasting glucose, fasting insulin, and HbA1c over time is how that trade-off is made visible rather than assumed.

Regulatory status, compounding, and 2026 context

Tesamorelin's only FDA-approved forms are the branded Egrifta line from Theratechnologies: the original Egrifta cleared in 2010, a reformulated Egrifta SV approved in 2019, and a further formulation, Egrifta WR, approved in 2025. The approved indication is narrow: reduction of excess abdominal fat in adults with HIV and lipodystrophy. It is not approved for general weight loss, athletic use, or anti-aging, and the labeling contraindicates active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis, reflecting the caution around stimulating the growth hormone and IGF-1 pathway.

Supply outside that branded indication is where the picture gets murky. Because tesamorelin is a 44-amino-acid peptide, it falls under the 2020 framework that regulates peptides longer than 40 amino acids as biologics, which places it outside the usual pharmacy-compounding pathway that applies to shorter peptides. In practice, most non-branded tesamorelin comes from research-chemical suppliers of uncertain quality rather than from a legitimately compounded or branded source, and the regulatory environment for peptides has continued to shift through 2025 and into 2026. Because the status is changing and gray-market sources routinely misstate it, the current regulatory and compounding position is worth verifying with a licensed clinician or pharmacist rather than assuming it from a vendor page.

Biomarkers to Track

When running Tesamorelin, these are the biomarkers most commonly tracked to assess response and safety:

Blood Work Checklist

Before starting Tesamorelin, baseline the right panel. The Peptide Blood Work Checklist covers the full baseline panel, what to add for Tesamorelin's class, and when to retest.

Reconstitution Calculator

Free calculator for Tesamorelin reconstitution math - vial size, BAC water volume, and exact syringe units.

Side Effects & Monitoring

What Tesamorelin side effects are commonly reported, when they appear, the red flags worth a provider call, and the biomarkers that catch issues early.

Results & What to Track

What Tesamorelin results actually look like in the data - the markers to measure, when they tend to move, and how to tell a real result from placebo.

Related Reading

• Tesamorelin Igf1 Results →
• Sermorelin Vs Tesamorelin →
• Igf 1 Blood Test Guide →

Related Peptides

Stacks That Include Tesamorelin

Tesamorelin Head-to-Head Comparisons

Conditions Tesamorelin is Commonly Researched For

Frequently Asked Questions

Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.